Carcinoma, Transitional Cell research hub
15 indexed studies · 8 currently recruiting
- recruitingPHASE3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
This study is testing a new medicine, vepugratinib, for advanced or spread bladder cancer. It will be given with two other drugs, enfortumab vedotin and pembrolizumab, to see if it's safe and helps. It’s compared to a dummy medicine (placebo).
United States · Australia · Brazil - authorisedHuman Pharmacology (Phase I)- First administration to humans
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
This study is testing a new medicine called LY4257496 for people with certain types of cancer, including breast, bowel, prostate, and womb cancer, especially if it has spread. It's the first time this medicine is being given to people, to check if it's safe and how it works in the body.
Germany - active not recruiting
Virtual Reality for Advanced Cancer Pain
This study aims to develop and test a virtual reality (VR) program to help people with advanced cancer manage their pain. Researchers will work with patients to create a VR experience that is effective, easy to use, and enjoyable, hoping it could offer a new way to cope with pain.
United Kingdom - active not recruitingPHASE2
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This study is for people with cancer that has spread, who are already benefiting from a specific medicine called trastuzumab emtansine (T-DM1) or other similar treatments in an earlier study. It allows them to keep receiving these important treatments for longer to see if they continue to help.
United States · Australia · Belgium - active not recruitingPHASE1
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
This study tests a new medicine called zongertinib for advanced cancers with changes in the HER2 gene. It aims to find the right dose and see if it can shrink tumours, especially in non-small cell lung cancer.
United States · Australia · Austria - recruitingPHASE3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
United States · Australia · Austria - recruitingPHASE1
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
This study is looking at a new medicine called LOXO-435 for cancers, especially bladder cancer, that have a specific gene change (FGFR3). It checks how safe and effective LOXO-435 is, both alone and with other standard treatments, to see if it can help patients.
United States · Australia · Canada - recruitingPHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This study looks at a new drug, olomorasib, combined with other treatments for advanced lung cancer. It’s for people whose cancer has a specific change called KRAS G12C and haven't had previous treatment for advanced disease. The aim is to see if this new combination works better than standard care.
United States · Australia · Austria - recruitingPHASE3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
This study is for people with advanced breast cancer that has a specific genetic change (PIK3CA). It's testing a new drug, Tersolisib, alongside other cancer medicines, to see if it's safe and helps treat the disease effectively.
United States · Argentina · Australia - recruiting
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
This study looks at how a new breast cancer treatment, trastuzumab deruxtecan (T-DXd), works in real life for people with advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It will also gather information on how patients feel and their experiences with the treatment.
Germany - active not recruitingPHASE3
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
This study for advanced ER+, HER2- breast cancer tests a new drug called imlunestrant. Researchers want to see if it works better than standard hormone therapy, and if adding abemaciclib helps even more. It aims to find better treatments for this common type of breast cancer.
United States · Argentina · Australia - recruitingPHASE1
A Study of LY4175408 in Participants With Advanced Cancer
This study is looking at a new medicine called LY4175408 for people with certain advanced cancers, including lung, womb, and a type of breast cancer. It aims to see if the medicine is safe, how well it works, and how the body handles it.
United States · China · France - active not recruitingPHASE1
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
This study is testing a new medicine, MK-6837, by itself and with another drug, pembrolizumab. It's for people with advanced cancers that haven't responded to usual treatments. The main goals are to check its safety and how well people tolerate it.
United States · Australia · Canada - not yet recruitingPHASE2
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
This study looks at two different drugs, sacituzumab govitecan and trastuzumab deruxtecan, for advanced triple-negative breast cancer. Researchers are testing if using them in an alternating pattern improves survival compared to using sacituzumab govitecan alone.
France - active not recruitingPHASE3
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
This study looks at a new drug, abemaciclib, combined with standard treatment for prostate cancer that has spread. We want to see if this combination can stop the cancer from getting worse for longer in men whose cancer is still responding to hormone therapy.
United States · Argentina · Australia